CancerDrs

Lung Cancer clinical trials in Georgia

34 actively recruiting lung cancer trials at 23 sites across Georgia.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in Georgia:
  • CTCA at Southeastern Regional Medical Center — Newnan, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Georgia:
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
  • Emory Decatur Hospital — Decatur, Georgia
  • Emory Johns Creek Hospital — Johns Creek, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Georgia:
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Piedmont Hospital — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
  • WellStar Cobb Hospital — Austell, Georgia
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Georgia:
  • University Cancer & Blood Center (UCBC) - Athens — Athens, Georgia
  • Local Institution - Unk052 — Atlanta, Georgia
  • Local Institution - 007-786-C — Carrollton, Georgia
  • Local Institution - 007-786-A — Cartersville, Georgia
  • Local Institution - 007-786-D — Douglasville, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Georgia:
  • Research Site — Athens, Georgia
  • Research Site — Atlanta, Georgia
  • Research Site — Savannah, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in Georgia:
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0012) — Marietta, Georgia
  • Southeastern Regional Medical Center ( Site 0098) — Newnan, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Sponsor: Amgen
NCT ID: NCT07005128
Sites in Georgia:
  • Central Georgia Cancer Care PC — Macon, Georgia
  • City of Hope Atlanta — Newnan, Georgia
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Georgia:
  • Piedmont Healthcare — Atlanta, Georgia
  • John B Amos Cancer Center — Columbus, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…

Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in Georgia:
  • Piedmont Cancer Institute — Atlanta, Georgia
  • Northwest Georgia Oncology Centers — Marietta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03191149
Sites in Georgia:
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Georgia:
  • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler — Savannah, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…

Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in Georgia:
  • Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…

Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Georgia:
  • Winship Cancer Institute - Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

This phase II trial tests the impact of biomarkers in predicting initial treatment (first-line) PD1 or PD-L1 (PD\[L\]-1)-based immunotherapy response and in selecting second-line treatment in patients with stage IIIB-IV non-small cell lung…

Sponsor: City of Hope Medical Center
NCT ID: NCT07288034
Sites in Georgia:
  • City of Hope Atlanta Cancer Center — Newnan, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).

Sponsor: Teligene US
NCT ID: NCT06010329
Sites in Georgia:
  • University Cancer & Blood Center (UCBC) - Athens — Athens, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Beta-only IL-2 ImmunoTherapY Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibi…

Sponsor: Medicenna Therapeutics, Inc.
NCT ID: NCT05086692
Sites in Georgia:
  • Emory - Winship Cancer Institute — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

Sponsor: Teligene US
NCT ID: NCT05168566
Sites in Georgia:
  • University Cancer & Blood Center — Athens, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumo…

Sponsor: Molecular Partners AG
NCT ID: NCT07278479
Sites in Georgia:
  • Emory University Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

This phase II trial tests how well defactinib and avutometinib in combination with nivolumab works in treating patients with LKB1-mutant non-small cell lung cancer that has not responded (refractory) to an anti-PD1 treatment and may have s…

Sponsor: Emory University
NCT ID: NCT06495125
Sites in Georgia:
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

This clinical trial tests proton beam radiation therapy in patients with non-small cell lung cancer who have undergone surgical resection and have lymph nodes involving the middle of the chest. Proton therapy is a type of radiation treatme…

Sponsor: Emory University
NCT ID: NCT06008730
Sites in Georgia:
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…

Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in Georgia:
  • Emory University School of Medicine — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of XB010 in Subjects With Solid Tumors

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumo…

Sponsor: Exelixis
NCT ID: NCT06545331
Sites in Georgia:
  • Winship Cancer Institute — Atlanta, Georgia
View on ClinicalTrials.gov →

Showing 25 of 34 trials with sites in Georgia. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07